ATMEKSI (methocarbamol) · ROSEMONT PHARMS
ATMEKSI (methocarbamol) oral suspension is a muscle relaxant indicated as: an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients 16 and older. 1.1 Acute, painful musculoskeletal conditions.
Details
- Status
- Prescription
- First Approved
- 2025-07-30
- Patent Cliff
- 2044
- Routes
- ORAL
- Dosage Forms
- SUSPENSION
ATMEKSI Approval History
What ATMEKSI Treats
1 indicationsATMEKSI is approved for 1 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Musculoskeletal Conditions
Drugs Similar to ATMEKSI
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
6 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05603832 | 100-CIP02-P | Ph 3 | completed | A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement |
| NCT05388929 | 1913843 | Ph 4 | active not recruiting | Methocarbamol in Ventral and Inguinal HR |
| NCT05076110 results posted | 21-003441 | Ph 4 | completed | Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures |
| NCT02432456 results posted | PRO00024679 | Ph 4 | completed | Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients |
| NCT02831569 results posted | 1387.1 | Ph 3 | completed | Japanese IP-TN Trial |
| NCT02665286 results posted | 2015-5903 | Ph 4 | completed | Orphenadrine and Methocarbamol for LBP |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ATMEKSI FDA Label Details
Indications & Usage
FDA Label (PDF)ATMEKSI (methocarbamol) oral suspension is a muscle relaxant indicated as: an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients 16 and older. 1.1 Acute, painful musculoskeletal conditions. ATMEKSI is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients 16 and older.
ATMEKSI Patents & Exclusivity
Patents (1 active)
Pro Intelligence Preview
Deep insights for ATMEKSI
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2044
- • 2 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 1 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.